Epitope-positive truncating MLH1 mutation and loss of PMS2: Implications for IHC-directed genetic testing for lynch syndrome

Israel Zighelboim, Matthew A. Powell, Sheri A. Babb, Alison J. Whelan, Amy P. Schmidt, Mark Clendenning, Leigha Senter, Stephen N Thibodeau, Albert De La Chapelle, Paul J. Goodfellow

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We assessed mismatch repair by immunohistochemistry (IHC) and microsatellite instability (MSI) analysis in an early onset endometrial cancer and a sister's colon cancer. We demonstrated high-level MSI and normal expression for MLH1, MSH2 and MSH6. PMS2 failed to stain in both tumors, strongly implicating a PMS2 defect. This family did not meet clinical criteria for Lynch syndrome. However, early onset endometrial cancers in the proband and her sister, a metachronous colorectal cancer in the sister as well as MSI in endometrial and colonic tumors suggested a heritable mismatch repair defect. PCR-based direct exonic sequencing and multiplex ligation-dependent probe amplification (MLPA) were undertaken to search for PMS2 mutations in the germline DNA from the proband and her sister. No mutation was identified in the PMS2 gene. However, PMS2 exons 3, 4, 13, 14, 15 were not evaluated by MLPA and as such, rearrangements involving those exons cannot be excluded. Clinical testing for MLH1 and MSH2 mutation revealed a germline deletion of MLH1 exons 14 and 15. This MLH1 germline deletion leads to an immunodetectable stable C-terminal truncated MLH1 protein which based on the IHC staining must abrogate PMS2 stabilization. To the best of our knowledge, loss of PMS2 in MLH1 truncating mutation carriers that express MLH1 in their tumors has not been previously reported. This family points to a potential limitation of IHC-directed gene testing for suspected Lynch syndrome and the need to consider comprehensive MLH1 testing for individuals whose tumors lack PMS2 but for whom PMS2 mutations are not identified.

Original languageEnglish (US)
Pages (from-to)501-504
Number of pages4
JournalFamilial Cancer
Volume8
Issue number4
DOIs
StatePublished - Dec 2009

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Genetic Testing
Microsatellite Instability
Epitopes
Immunohistochemistry
Exons
Mutation
DNA Mismatch Repair
Multiplex Polymerase Chain Reaction
Endometrial Neoplasms
Neoplasms
Germ-Line Mutation
Colonic Neoplasms
Genes
Colorectal Neoplasms
Coloring Agents
Staining and Labeling
Polymerase Chain Reaction
DNA

Keywords

  • Immunohistochemistry
  • Lynch syndrome
  • Microsatellite instability
  • Mismatch repair genes
  • MLH1
  • PMS2
  • Testing

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Oncology
  • Genetics(clinical)

Cite this

Zighelboim, I., Powell, M. A., Babb, S. A., Whelan, A. J., Schmidt, A. P., Clendenning, M., ... Goodfellow, P. J. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: Implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 8(4), 501-504. https://doi.org/10.1007/s10689-009-9276-2

Epitope-positive truncating MLH1 mutation and loss of PMS2 : Implications for IHC-directed genetic testing for lynch syndrome. / Zighelboim, Israel; Powell, Matthew A.; Babb, Sheri A.; Whelan, Alison J.; Schmidt, Amy P.; Clendenning, Mark; Senter, Leigha; Thibodeau, Stephen N; De La Chapelle, Albert; Goodfellow, Paul J.

In: Familial Cancer, Vol. 8, No. 4, 12.2009, p. 501-504.

Research output: Contribution to journalArticle

Zighelboim, I, Powell, MA, Babb, SA, Whelan, AJ, Schmidt, AP, Clendenning, M, Senter, L, Thibodeau, SN, De La Chapelle, A & Goodfellow, PJ 2009, 'Epitope-positive truncating MLH1 mutation and loss of PMS2: Implications for IHC-directed genetic testing for lynch syndrome', Familial Cancer, vol. 8, no. 4, pp. 501-504. https://doi.org/10.1007/s10689-009-9276-2
Zighelboim, Israel ; Powell, Matthew A. ; Babb, Sheri A. ; Whelan, Alison J. ; Schmidt, Amy P. ; Clendenning, Mark ; Senter, Leigha ; Thibodeau, Stephen N ; De La Chapelle, Albert ; Goodfellow, Paul J. / Epitope-positive truncating MLH1 mutation and loss of PMS2 : Implications for IHC-directed genetic testing for lynch syndrome. In: Familial Cancer. 2009 ; Vol. 8, No. 4. pp. 501-504.
@article{e50361752344431cae818a37d7e91195,
title = "Epitope-positive truncating MLH1 mutation and loss of PMS2: Implications for IHC-directed genetic testing for lynch syndrome",
abstract = "We assessed mismatch repair by immunohistochemistry (IHC) and microsatellite instability (MSI) analysis in an early onset endometrial cancer and a sister's colon cancer. We demonstrated high-level MSI and normal expression for MLH1, MSH2 and MSH6. PMS2 failed to stain in both tumors, strongly implicating a PMS2 defect. This family did not meet clinical criteria for Lynch syndrome. However, early onset endometrial cancers in the proband and her sister, a metachronous colorectal cancer in the sister as well as MSI in endometrial and colonic tumors suggested a heritable mismatch repair defect. PCR-based direct exonic sequencing and multiplex ligation-dependent probe amplification (MLPA) were undertaken to search for PMS2 mutations in the germline DNA from the proband and her sister. No mutation was identified in the PMS2 gene. However, PMS2 exons 3, 4, 13, 14, 15 were not evaluated by MLPA and as such, rearrangements involving those exons cannot be excluded. Clinical testing for MLH1 and MSH2 mutation revealed a germline deletion of MLH1 exons 14 and 15. This MLH1 germline deletion leads to an immunodetectable stable C-terminal truncated MLH1 protein which based on the IHC staining must abrogate PMS2 stabilization. To the best of our knowledge, loss of PMS2 in MLH1 truncating mutation carriers that express MLH1 in their tumors has not been previously reported. This family points to a potential limitation of IHC-directed gene testing for suspected Lynch syndrome and the need to consider comprehensive MLH1 testing for individuals whose tumors lack PMS2 but for whom PMS2 mutations are not identified.",
keywords = "Immunohistochemistry, Lynch syndrome, Microsatellite instability, Mismatch repair genes, MLH1, PMS2, Testing",
author = "Israel Zighelboim and Powell, {Matthew A.} and Babb, {Sheri A.} and Whelan, {Alison J.} and Schmidt, {Amy P.} and Mark Clendenning and Leigha Senter and Thibodeau, {Stephen N} and {De La Chapelle}, Albert and Goodfellow, {Paul J.}",
year = "2009",
month = "12",
doi = "10.1007/s10689-009-9276-2",
language = "English (US)",
volume = "8",
pages = "501--504",
journal = "Familial Cancer",
issn = "1389-9600",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Epitope-positive truncating MLH1 mutation and loss of PMS2

T2 - Implications for IHC-directed genetic testing for lynch syndrome

AU - Zighelboim, Israel

AU - Powell, Matthew A.

AU - Babb, Sheri A.

AU - Whelan, Alison J.

AU - Schmidt, Amy P.

AU - Clendenning, Mark

AU - Senter, Leigha

AU - Thibodeau, Stephen N

AU - De La Chapelle, Albert

AU - Goodfellow, Paul J.

PY - 2009/12

Y1 - 2009/12

N2 - We assessed mismatch repair by immunohistochemistry (IHC) and microsatellite instability (MSI) analysis in an early onset endometrial cancer and a sister's colon cancer. We demonstrated high-level MSI and normal expression for MLH1, MSH2 and MSH6. PMS2 failed to stain in both tumors, strongly implicating a PMS2 defect. This family did not meet clinical criteria for Lynch syndrome. However, early onset endometrial cancers in the proband and her sister, a metachronous colorectal cancer in the sister as well as MSI in endometrial and colonic tumors suggested a heritable mismatch repair defect. PCR-based direct exonic sequencing and multiplex ligation-dependent probe amplification (MLPA) were undertaken to search for PMS2 mutations in the germline DNA from the proband and her sister. No mutation was identified in the PMS2 gene. However, PMS2 exons 3, 4, 13, 14, 15 were not evaluated by MLPA and as such, rearrangements involving those exons cannot be excluded. Clinical testing for MLH1 and MSH2 mutation revealed a germline deletion of MLH1 exons 14 and 15. This MLH1 germline deletion leads to an immunodetectable stable C-terminal truncated MLH1 protein which based on the IHC staining must abrogate PMS2 stabilization. To the best of our knowledge, loss of PMS2 in MLH1 truncating mutation carriers that express MLH1 in their tumors has not been previously reported. This family points to a potential limitation of IHC-directed gene testing for suspected Lynch syndrome and the need to consider comprehensive MLH1 testing for individuals whose tumors lack PMS2 but for whom PMS2 mutations are not identified.

AB - We assessed mismatch repair by immunohistochemistry (IHC) and microsatellite instability (MSI) analysis in an early onset endometrial cancer and a sister's colon cancer. We demonstrated high-level MSI and normal expression for MLH1, MSH2 and MSH6. PMS2 failed to stain in both tumors, strongly implicating a PMS2 defect. This family did not meet clinical criteria for Lynch syndrome. However, early onset endometrial cancers in the proband and her sister, a metachronous colorectal cancer in the sister as well as MSI in endometrial and colonic tumors suggested a heritable mismatch repair defect. PCR-based direct exonic sequencing and multiplex ligation-dependent probe amplification (MLPA) were undertaken to search for PMS2 mutations in the germline DNA from the proband and her sister. No mutation was identified in the PMS2 gene. However, PMS2 exons 3, 4, 13, 14, 15 were not evaluated by MLPA and as such, rearrangements involving those exons cannot be excluded. Clinical testing for MLH1 and MSH2 mutation revealed a germline deletion of MLH1 exons 14 and 15. This MLH1 germline deletion leads to an immunodetectable stable C-terminal truncated MLH1 protein which based on the IHC staining must abrogate PMS2 stabilization. To the best of our knowledge, loss of PMS2 in MLH1 truncating mutation carriers that express MLH1 in their tumors has not been previously reported. This family points to a potential limitation of IHC-directed gene testing for suspected Lynch syndrome and the need to consider comprehensive MLH1 testing for individuals whose tumors lack PMS2 but for whom PMS2 mutations are not identified.

KW - Immunohistochemistry

KW - Lynch syndrome

KW - Microsatellite instability

KW - Mismatch repair genes

KW - MLH1

KW - PMS2

KW - Testing

UR - http://www.scopus.com/inward/record.url?scp=70449536487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449536487&partnerID=8YFLogxK

U2 - 10.1007/s10689-009-9276-2

DO - 10.1007/s10689-009-9276-2

M3 - Article

C2 - 19672700

AN - SCOPUS:70449536487

VL - 8

SP - 501

EP - 504

JO - Familial Cancer

JF - Familial Cancer

SN - 1389-9600

IS - 4

ER -